antibody drug conjugate Archives

Infographic showing the mechanism of action of Teclistamab where the bispecific antibody binds BCMA on myeloma cells and CD3 on T cells to activate cytotoxic T-cell signaling and tumor cell killing.

March 12, 2026March 24, 2026 Cancer Immunology

Teclistamab in Multiple Myeloma: Mechanism, Structure and Clinical Trial Results

Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more

Infographic showing BCMA-targeted therapies for multiple myeloma including bispecific antibody teclistamab, CAR-T cell therapy, and antibody-drug conjugate belantamab mafodotin.

March 12, 2026March 24, 2026 Cancer Immunology

BCMA-Targeted Therapies in Multiple Myeloma: Teclistamab vs CAR-T vs Antibody-Drug Conjugates

Compare BCMA therapies in multiple myeloma including Teclistamab, CAR-T therapy, and antibody-drug conjugates with mechanisms and clinical outcomes. Read more

BCMA signaling pathway cartoon diagram showing NF-κB, PI3K-AKT, and MAPK pathways activated by BCMA in multiple myeloma cells

March 12, 2026March 24, 2026 Cancer Immunology

BCMA Signaling Pathway in Multiple Myeloma: Structure, Function and Therapeutic Targeting

BCMA signaling drives plasma cell survival in multiple myeloma through BAFF/APRIL activation of NF-κB, PI3K-AKT, and MAPK pathways. Read more

S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31